Proteinuria
Case study in CKD illustrates need for better communication between physicians, patients
VIDEO: Inrig discusses outcomes, developments for adults with IgA nephropathy
PHILADELPHIA — Sparsentan was shown to be safe and well-tolerated, and reduced proteinuria in adults with IgA nephropathy, according to studies presented at ASN Kidney Week.
VIDEO: Sparsentan well-tolerated, demonstrated sustained anti-proteinuria effects
PHILADELPHIA — Sparsentan was shown to be well-tolerated and demonstrated sustained anti-proteinuria effects at the final analysis of 110 weeks, according to research presented at ASN Kidney Week.
VIDEO: Sparsentan reduced proteinuria in patients with focal segmental glomerulosclerosis
PHILADELPHIA — Patients with focal segmental glomerulosclerosis had clinically meaningful and durable reduction in proteinuria with sparsentan treatment, according to phase 3 DUPLEX Trial data presented at ASN Kidney Week, here.
Omeros: Narsoplimab results ‘not what we expected’ for treating proteinuria, ends trial
An interim analysis of outcomes from a phase 3 trial evaluating narsoplimab for the treatment of immunoglobulin A nephropathy showed the reduction in proteinuria from baseline did not reach statistical significance compared with placebo.
Trial results show decrease in proteinuria, stabilized GFR with IgA nephropathy drug
Results from a phase 2 trial of a new drug to treat IgA nephropathy showed a reduction in proteinuria and stabilization of eGFR vs. controls after 36 weeks, according to a presentation at the European Renal Association Congress.
Sparsentan demonstrates sustained decline of proteinuria in patients with IgA nephropathy
Daily treatment of sparsentan led to a greater reduction of proteinuria in patients with IgA nephropathy compared with irbesartan treatment, according to a study published in The Lancet.
FDA grants accelerated approval to Filspari for reduced proteinuria in IgA nephropathy
Travere Therapeutics announced the FDA granted accelerated approval to Filspari, also known as sparsentan, according to a company press release.
CVD death common among individuals with reduced eGFR, regardless of CKD progression
Irrespective of chronic kidney disease progression, the most common cause of death among individuals with a reduced eGFR was death due to cardiovascular disease, according to data published in Kidney Medicine.
Elevated urinary protein associated with HF events in patients with AF
Among Japanese patients with atrial fibrillation, elevated urinary protein may be an independent risk factor for HF events, according to a study published in European Heart Journal - Quality of Care and Clinical Outcomes.